Multiple Sclerosis

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 6, 2024.

MRI scans showed that 99% of fenebrutinib-treated patients were free of T1 gadolinium-enhancing lesions, indicating minimal active inflammation.

Tolebrutinib, a brain-penetrant BTK inhibitor, achieved the primary endpoint in the HERCULES study, significantly reducing disability accumulation in patients with non-relapsing secondary progressive multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 30, 2024.

ABA-101 has shown promising safety and anti-inflammatory effects in animal models, and Abata Therapeutics plans to initiate a Phase 1 study in 2024 to evaluate its potential for treating progressive multiple sclerosis.

IMU-838 daily doses of 30-mg and 45-mg suppressed the development of gadolinium-enhancing lesions by 78% and 74% compared with the placebo at 24 weeks in relapsing-remitting multiple sclerosis.

The postdoctoral researcher at Amsterdam University Medical Center introduces the DAAE score, a tool used to predict a patient's risk of transition to secondary progressive multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 23, 2024.

The postdoctoral researcher at Amsterdam University Medical Center talked about the development of the DAAE score, a tool for predicting the risk of transition to secondary progressive multiple sclerosis. [WATCH TIME: 8 minutes]

In this episode, Patricia Coyle, MD, FAAN, gave clinical insight on some of the next steps regarding S1P-modulating therapies, including some of the advantages of newer generation agents and the need for future studies to investigate benefits and limitations to each.

In this episode, Adnan Subei, DO, gave clinical background on ozanimod, the supportive trials behind the drug, and its known efficacy and safety profile to date.

Neurologist Adnan Subei, DO, gave clinical background on ozanimod, the supportive trials behind the drug, and its known efficacy and safety profile to date.

In this episode, Adnan Subei, DO, FAAN, discusses siponimod, a selective S1P receptor modulator approved in 2019, its clinical advantages, efficacy, and how it may be useful for patients with multiple sclerosis.

Acute clinical events with stable MRI were more likely among patients with multiple sclerosis who had longer disease duration, received highly effective disease-modifying therapies, and were presented with fatigue.

In this episode, Patricia Coyle, MD, FAAN, provides in-depth insight on fingolimod, the first approved S1P receptor modulator, and the clinical data pre- and post-approval.

In this episode, Patricia Coyle, MD, FAAN, describes the development of S1P modulator receptors, their mechanism of action, potential side effects, and considerations for patient suitability, particularly in comparison to other treatment options like monoclonal antibodies.

Epstein-Barr Virus-specific T cells in multiple sclerosis (MS) showed significant autoreactivity to central nervous system antigens, indicating a potential mechanism for MS-related damage.

Results showed that the DAAE Score performs well, with consistent risk estimates across the derivation (JMSC), internal-validation (JMSC), and external-validation (MSCA) dataset across treatment centers internationally.

Earlier this year, IDP-023 received fast track designation by the FDA for the treatment of patients with multiple myeloma and non-Hodgkin lymphoma.

Here's the latest multidisciplinary multiple sclerosis (MS) research from the International Journal of MS Care.

Tiziana Life Sciences’ intranasal foralumab has shown potential in treating nonactive secondary progressive multiple sclerosis through innovative immune modulation.

With the approved IND, it expands research efforts of equecabtagene autoleucel from other autoimmune conditions like myasthenia gravis and NMOSD.

NeurologyLive joins the CMSC in mourning the loss of founder and CEO,June Halper, MSN, APC-C, MSCN, FAAN.

Antonella Favit-Van Pelt, MD, PhD, chief medical officer at Helius Medical Technologies, gave perspective on the clinical advantages of the company’s non-implantable device to treat gait in multiple sclerosis.

The professor of neurology at Stony Brook Medicine talked about the promising potential in ongoing studies assessing BTK inhibitors as treatment for primary progressive multiple sclerosis. [WATCH TIME: 3 minutes]